IDEXX Stock Has Rallied 40% Over the Past Year: Can a New CEO Keep the Momentum Going?

robot
Abstract generation in progress

IDEXX Laboratories recently announced Michael Erickson will succeed Jay Mazelsky as CEO, following a year where shares surged significantly. Despite beating Q4 revenue estimates, concerns arose from a guided 2% decline in U.S. same-store clinical visits, causing a slight stock dip. Analysts project a potential 38% upside to $873 by December 2028, contingent on sustained 9% revenue growth and 33% operating margins, though the exit multiple already aligns with current market pricing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin